H-D-(αMe)Phe-OMe*HCl | 84120-87-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: H-D-(αMe)Phe-OMe*HCl
• 英文别名: (R)-α-methylphenylalanine methyl ester hydrochloride；(R)-α-MePheOMe*HCl；D-α-methylphenylalanine methyl ester hydrochloride；(-)-(2R)-methyl 2-amino-2-methyl-3-phenylpropanoate hydrochloride；α-methyl-DL-phenylalanine methyl ester hydrochloride；D,L-α-methylphenylalanine methyl ester hydrochloride；α-methyl-L-phenylalanine methyl ester hydrochloride；(R)-Methyl 2-amino-2-methyl-3-phenylpropanoate hydrochloride；methyl (2R)-2-amino-2-methyl-3-phenylpropanoate;hydrochloride
• CAS: 84120-87-6
• 化学式: C₁₁H₁₅NO₂*ClH
• 分子量: 229.707
• InChiKey: VUYGLGCVKCLWPY-RFVHGSKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.54
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  H-D-(αMe)Phe-OMe*HCl 在 N-甲基吗啉 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 (R)-Hippuryl-alpha-methylphenylalanine
  参考文献：
  名称：

  Hippuryl-α-methylphenylalanine and hippuryl-α-methylphenyllactic acid as substrates for carboxypeptidase A. Syntheses, kinetic evaluation and mechanistic implication

  摘要：

  (R)- and (S)-Hippuryl-alpha-methylphenylalanine [(R)- and (S)-Hipp-alpha-MePhe] and (S)-hippuryl-alpha-methylphenyllactic acid [(S)-Hipp-alpha-MeOPhe] were synthesized and evaluated as substrates for carboxypeptidase A (CPA) in an effort to shed further light on the catalytic mechanism of the enzyme. The rate of CPA-catalyzed hydrolysis of (S)-Hipp-alpha-MePhe was reduced by 105-fold compared with that of (S)-Hipp-Phe. but the hydrolysis rate of (S)-Hipp-OPhe was lowered by only 6.8-fold by the introduction of a methyl group at the alpha-position. (R)-Hipp-alpha-MePhe failed to be hydrolyzed initially, then started to undergo hydrolysis in about 2 h at a much reduced rate. The results of present study may be envisioned on the basis of the proposition that while peptide substrate is hydrolyzed via a tetrahedral transition state formed by the attack of the zinc-bound water molecule at the peptide carbonyl carbon, ester hydrolysis takes the path that involves an anhydride intermediate generated by the attack of the carboxylate of Glu-270 at the ester carbonyl carbon, (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00006-7
• 作为产物：
  描述：

  溴甲苯 在 盐酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 3.0h， 生成 H-D-(αMe)Phe-OMe*HCl
  参考文献：
  名称：

  Flexible Synthesis and Evaluation of Diverse Anti-Apicomplexa Cyclic Peptides

  摘要：

  A modular approach to synthesize anti-Apicomplexa parasite inhibitors was developed that takes advantage of a pluripotent cyclic tetrapeptide scaffold capable of adjusting appendage and skeletal diversities in only a few steps (one to three steps). The diversification processes make use of selective radical coupling reactions and involve a new example of a reductive carbon nitrogen cleavage reaction with SmI2. The resulting bioactive cyclic peptides have revealed new insights into structural factors that govern selectivity between Apicomplexa parasites such as Toxoplasma and Plasmodium and human cells.

  DOI：

  10.1021/jo4001492

文献信息

• [EN] BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE BENZYLETHER ET BENZYLAMINO DE BETA-SECRETASE POUR TRAITER LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2005051914A1

  公开（公告）日：2005-06-09

  The present invention is directed to benzylether and benzylamino derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及苯乙醚和苄胺衍生物化合物，这些化合物是β-分泌酶的抑制剂，并且在治疗涉及β-分泌酶的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶的这类疾病中使用这些化合物和组合物。
• Antihypertensive compositions containing an aryl-substituted alanine azo
  申请人：Merck & Co., Inc.

  公开号：US04156734A1

  公开（公告）日：1979-05-29

  Novel pharmaceutical compositions are disclosed. The compositions comprise an aryl substituted alanine and a substituted phenyl hydrazino propionic acid. The compositions are useful for treating hypertension.

  新型药物组合物已被披露。该组合物包括一种芳基取代的丙氨酸和一种取代的苯基肼丙酸。该组合物可用于治疗高血压。
• Amino acids and esters thereof useful as antihypertensive agents
  申请人：Merck & Co., Inc.

  公开号：US04065572A1

  公开（公告）日：1977-12-27

  A compound of the formula ##STR1## possesses antihypertensive activity. Also provided are methods for the preparation of the compounds as well as pharmaceutical formulations and methods for their use as antihypertensive agents.

  一种具有抗高血压活性的化合物的分子式为##STR1##。还提供了制备这些化合物的方法，以及作为抗高血压药剂使用的药物配方和方法。
• Metallkomplexe von biologisch wichtigen Liganden, CXXIX [1]. Palladium(II)-und Platin(II)-Komplexe von 4,4-disubstituierten Oxazolonen und C2-symmetrischen Bis(oxazolonen) Metal Complexes of Biologically Important Ligands, CXXIX [1]. Palladium(II) and Platinum(II) Complexes of 4,4-Disubstituted Oxazolones and of C₂-Symmetric Bis(oxazolones)
  作者：Werner Bauer、Walter Ponikwar、Wolfgang Beck

  DOI：10.1515/znb-2000-1009

  日期：2000.10.1

  4H)-oxazolone (1) forms with the chloro bridged compounds [R3PMCl2]2 (M = Pt, Pd) the complexes Cl2Pt(PR3)(l) (R = Et, nBu) and Cl2Pd(PEt3)(l). The enantiomeric pure C2-symmetric CMe2 bridged bis(oxazolones) 5 and 6 have also been employed which give with PdCl2 the chelate complexes 13 and 14. The X-ray structural determination of Cl2P d[O-C (O)-CMe2-N=C-CMe2-C=N-CMe2-C (O)-O ] (10) shows that one

  摘要 4-Benzyl-4-methyl-2-phenyl-5(4H)-oxazolone (1) 与氯桥化合物 [R3PMCl2]2 (M = Pt, Pd) 形成配合物 Cl2Pt(PR3)(l) (R = Et, nBu) 和 Cl2Pd(PEt3)(l)。还使用了对映体纯 C2-对称 CMe2 桥连双（恶唑酮）5 和 6，它们与 PdCl2 形成螯合物 13 和 14。 Cl2P d[OC (O)-CMe2-N=C 的 X 射线结构测定-CMe2-C=N-CMe2-C (O)-O ] (10) 表明 CMe2 桥的甲基之一位于钯原子附近。这也可以在 1H NMR 谱中检测到。
• Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
  申请人：Nantermet G. Philippe

  公开号：US20070088165A1

  公开（公告）日：2007-04-19

  The present invention is directed to benzylether and benzylamino derivative compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的苯甲醚和苯甲氨基衍生物化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶涉及的疾病，例如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及在治疗β-分泌酶酶涉及的疾病中使用这些化合物和组合物的用途。